MANAGE-SMA Study
Effect of higher-dose nusinersen therapy in the PRaxis
The MANAGE-SMA study investigates treatment experience, treatment satisfaction and motor function in adult patients with 5q-SMA. The therapies being studied are nusinersen 12 mg, risdiplam and the higher-dose nusinersen therapy (50/28 mg).
The MANAGE-SMA study is a longitudinal, non-interventional, observational, non-randomized, multi-center study with a total of 110 participants. The aim is to better understand the effect of the higher-dose nusinersen treatment regimen under everyday conditions in clinical practice.
In particular, the following are recorded:
Management of the program
Do you have questions about the MANAGE-SMA study? I will be happy to help you!
Dr. Ronja Schiemann
Clinical research associate